Savient Pharmaceuticals appoints president of Savient Europe
David Veitch takes up the role
Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient's European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.
Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.
Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.
Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.
Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.
You may also like
Pharmaceutical
Optimising process steps and performance with agitated Nutsche filter-dryers
Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
Sustainability
ACG Packaging Materials becomes first pharma packaging firm to join WEF Lighthouse Network
The company has joined the World Economic Forum’s Global Lighthouse Network after its Shirwal facility was named a Lighthouse site, making it the world’s first pharmaceutical packaging company to receive the recognition for smart, sustainable manufacturing
Pharmaceutical
testo Saveris 1 update automates environmental monitoring workflows for pharma compliance
New features include automated workflows for efficient environmental monitoring, approvals for secure and compliant changes, and more flexible control of webhooks, as well as further improvements in performance, transparency and usability
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies